Neel R. Desai, MD, explains how the Softec HD IOL (Lenstec) benefits his practice. He describes the outcome-based conversations he has with patients about this lens and shares specific pearls for implanting this lens.​​

​Click on the image below to view the video. 
NOTE: YOU WILL BE REQUIRED TO REGISTER A NEW, FREE EYETUBE ACCOUNT TO VIEW THE VIDEO TO ITS ENTIRETY.

Lenstec has stated that it has won its UK patent suit against Oculentis for bifocal IOLs. Oculentis has withdrawn legal proceedings against Lenstec in the UK High Court and made a payment towards Lenstec’s legal costs, according to a Lenstec news release.

Lenstec has agreed not to pursue Oculentis for any additional costs in what Lenstec said was always considered to be a "frivolous lawsuit and without merit." Lenstec’s SBL-3 and SBL-2 IOLs use a patented design which does not infringe on any of Oculentis’ intellectual property.
​
In commenting on the resolution of the legal dispute, Lenstec stated that, “The cessation of the legal proceedings and acknowledgement by Oculentis that Lenstec did not infringe on their patent is very timely. On the one hand, Lenstec is close to completing enrollment in its US clinical trial for the SBL-3 lens, so it is commercially advantageous to us. Secondly, with the growing popularity of the Extended Depth of Focus lens category, it is a great time for us to reconnect with surgeons to reiterate that all of the trifocal and other multifocal lenses remain based on a concentric ring platform, and these are renowned for high levels of dysphotopsias (halos and glare). The bifocal platform is significantly less susceptible to dysphotopsias, leading to happier patients and reliable levels of near and intermediate vision. We look forward to redoubling our efforts in the multifocal category.”

http://eyewiretoday.com/2018/02/23/lenstec-and-oculentis-settle-legal-dispute-over-patents-for-bifocal-iols
​

Lenstec, Inc, a manufacturer of technologically advanced implantable lenses for correcting vision, today announced it has expanded its Softec HD product line with the Softec HDM, which was approved by the U.S. Food & Drug Administration in March..

ST. PETERSBURG, Florida, August 18, 2015—Lenstec, Inc.—an established medical device manufacturer of
technologically advanced implantable lenses for treating vision disorders—today announced the start of an
FDA trial in support of gaining FDA clearance for its Segmented Bi-focal lens (SBL-3).

ST PETERSBURG, FL - On Saturday, October 18, Lenstec employees gathered together for the Making Strides for Breast Cancer Walk in St Petersburg, Florida.  Over $900 was raised in support of one of our employees, Nouanthip "Cat" Manipakone, which was matched by Lenstec 100%.  All proceeds were donated to the American Cancer Society.

By William B. Trattler, M.D., Neel R. Desai, M.D., Carlos Buznego, M.D., and Gabriela Perez, B.S.

Cataract surgery has been touted as one of the most common operations in the United States with over 3 million procedures performed per year. Perhaps more impressively, this invasive procedure is also one of the most successful. With success rates estimated at ~99% and rapid technological advances over the past decade, both surgeons and
patients alike have become increasingly demanding of refractive perfection post cataract removal.